2022 Fiscal Year Final Research Report
Development of innovative drug dosage regimens compatible with diverse treatment responsiveness in depression and schizophrenia
Project/Area Number |
20K07134
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 47060:Clinical pharmacy-related
|
Research Institution | Kumamoto University |
Principal Investigator |
Saruwatari Junji 熊本大学, 大学院生命科学研究部(薬), 教授 (30543409)
|
Co-Investigator(Kenkyū-buntansha) |
古郡 規雄 獨協医科大学, 医学部, 准教授 (20333734)
城野 博史 熊本大学, 病院, 准教授 (40515483)
鬼木 健太郎 熊本大学, 大学院生命科学研究部(薬), 准教授 (00613407)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 精密医療 / 精神神経薬理学 / ファーマコメトリクス / 薬理ゲノム学 |
Outline of Final Research Achievements |
In this study, we attempted to predict treatment responsiveness based on patient information and other factors using the frequently used antidepressant paroxetine as the target drug. The results of the analysis using blood paroxetine concentration and MADRS as indices of treatment responsiveness showed that pharmacokinetic parameters in the first week after the start of treatment could effectively predict the amount of change in MADRS up to the 8th week thereafter. On the other hand, a search for factors associated with antipsychotic-induced metabolic abnormalities related to increased mortality in patients with schizophrenia revealed a higher frequency of overweight in female patients taking three or more antipsychotic medications and a higher frequency of overweight in both men and women taking high doses of risperidone.
|
Free Research Field |
臨床薬理学
|
Academic Significance and Societal Importance of the Research Achievements |
うつ病は人口の3%以上が、統合失調症は約1%が罹患する極めて頻度の高い精神疾患である。その治療の中心は薬物療法であるが、寛解・再発を繰り返し、約30%の患者で治療抵抗性を示す。加えて、抗精神病薬の長期投与では、肥満や糖尿病等の生活習慣病関連病態をきたし、服薬アドヒアランスの低下の他、生活の質(QOL)の低下や心血管イベントの増加(死亡率の増加)にも関係することが臨床で問題となっている。本研究の結果から、臨床薬学的検討により、うつ病や統合失調症の個別化投与設計が実現できる可能性を示すことが出来た。
|